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Microenvironment stimuliThe pathogenesis of bone metastasis is unclear, and much focus in metastatic biology and therapy relays on epi-
genetic alterations. Since DNA-methyltransferase blockade with 5-aza-2′-deoxycytidine (dAza) counteracts tu-
mour growth, here we utilized dAza to clarify whether molecular events undergoing epigenetic control were
critical for bone metastatization. In particular, we investigated the patterns of secreted-protein acidic and rich
in cysteine (SPARC) and of Endothelin 1, affected by DNA methyltransferases in tumours, with the hypothesis
that in bone metastasis a coordinate function of SPARC and Endothelin 1, if any occurs, was orchestrated by
DNA methylation. To this purpose, we prepared a xenograft model with the clone 1833, derived from human-
MDA-MB231 cells, and dAza administration slowed-down metastasis outgrowth. This seemed consequent to
the reductions of SPARC and Endothelin 1 at invasive front and in the bone marrow, mostly due to loss of
Twist. In the metastasis bulk Snail, partly reduced by dAza, might sustain Endothelin 1-SPARC cooperativity.
Both SPARC and Endothelin 1 underwent post-translational control by miRNAs, a molecular mechanism that
might explain the in vivo data. Ectopic miR29a reduced SPARC expression also under long-term dAza exposure,
while Endothelin 1 down-regulation occurred in the presence of endogenous-miR98 expression. Notably, dAza
effects differed depending on in vivo and in vitro conditions. In 1833 cells exposed to 30-days dAza, SPARC-
protein level was practically unaffected, while Endothelin 1 induction depended on the 3′-UTR functionality.
The blockade of methyltransferases leading to SPARC reduction in vivo, might represent a promising strategy
to hamper early steps of the metastatic process affecting the osteogenic niche.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The molecular events underlying the tropism for the secondary
organs represent an unresolved problem of the metastatic process. Me-
tastasis to bone is one of the most common and devastating complica-
tion in patients with advanced cancers of the breast, prostate or lung
[1]. Osteomimetic properties contribute to the preference of breast-
carcinoma metastasis for the bone, as exempliﬁed by Endothelin 1
axis that orchestrates signalling pathways including Runt-related tran-
scription factor 2 (Runx2) [2]. Also, the tumour-stroma interaction
and the composition of bonemicroenvironment are critical for skeleton
metastatization, favouring speciﬁc adhesion/recognition and invasion
[1,3–5]. The bone marrow is not conditioned by osseous metastatic
cells as extensively as stroma in pulmonary metastasis, and the sametor 2; SPARC, secreted protein
PPARγ, Peroxisome proliferator
hatase and tensin homolog;ME,
ilano, Dipartimento di Scienze
, Milano, Italy.
.mechanisms that govern the homing of hemopoietic stem cells in
healthy individuals are co-opted by tumour cells [1].
Secreted protein acidic and rich in cysteine (SPARC), a matricellular
glycoprotein, is associated with bone remodelling, repair, development,
cell turnover, mineralization process, and collagen ﬁbril assembly [3].
The SPARC function in tumorigenesis and tumour progression is still
controversial and not fully understood, and the different expression
and activity of SPARC depend on cancer type [6]. These diverse patterns
of SPARCwould be inﬂuenced by tumourmicroenvironment in terms of
local composition of matrix, molecules, cytokines and protease proﬁle,
while some inconsistencies are due to SPARC proteolytic products (pep-
tide fragments corresponding to different regions of SPARC) [3].
There are only few studies regarding prostate and breast cancer, that
try to disclose the roles of SPARC in bone metastasis [3]. Prostate carci-
noma PC3 cells on wild typematrices containing SPARC, show decrease
of cell proliferation and resistance to radiation-induced cell death, with
an increase in cell spreading [7]. SPARC gene is an earlymarker of poorly
differentiated phenotype, and high SPARC expression at the time of
prostatectomy is associated with development of metastasis [8]. Data
obtained with breast carcinoma MDA-MB231 cells, showing low
SPARC level [9] and added exogenous SPARC, lead to suppose its
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motility and chemoattraction towards vitronectin [10]. Adenovirally
produced SPARC, however, inhibits in vivo metastasis of MDA-MB231
cells into lung and bone, reducing the aggregation of tumour cells
with platelets [11].
While normal mammary tissue has undetectable or lightly detect-
able amounts of SPARC, and benign breast lesions are weakly positive,
75% of both in situ and invasive breast carcinomas are strongly positive
for SPARC in stromal cells (CD-34-negative, α-SMA-positive) [12,13];
breast carcinoma cells also show SPARC signal [14]. In various carcino-
mas, high SPARC expression is associated with signiﬁcantly poorer out-
comes compared with low SPARC expression [15].
Much focus in cancer biology and therapy deals with epigenetic
alterations that are drivers in neoplastic progression, and targeting the
molecular events regulated by DNA methylation may be an useful ap-
proach for chemoprevention [16,17]. Even if SPARC is methylated in a
300 bp CpG island spanning from exon 1 to intron 1 in many tumours
[18], the knowledge of the biological function and regulation of SPARC
by methylation in bone metastasis from breast carcinoma is scarce.
The aim of the present paper was to examine whether endogenous
SPARC plays a role in the metastatic process of breast carcinoma with
tropism for the skeleton, and whether SPARC is regulated by mecha-
nisms dependent on DNA-methyltransferases, to clarify the relevance
of methylation for metastasis outgrowth. To this end, a xenograft
model was prepared with the metastatic clone 1833 with bone
tropism- derived from invasive MDA-MB231 cells [19]- blocking DNA
methyltransferases with 5-aza-2′-deoxycytidine (decitabine, dAza).
dAza is a chemotherapic directly incorporated in the newly synthesized
DNA strands, that is in phase III trial for myeloid monocyte chronic leu-
kaemia, colangiocarcinoma and colon carcinoma [16,20]. Of note, dAza
has never been used to ﬁght bone metastasis from breast carcinoma.
The signiﬁcance of our study in vivo would be to identify the network
of molecular events implicated in SPARC expression both in metastatic
cells and microenvironment under DNA methyltransferases, that
might include the transcription factors Twist and Snail, and the biolog-
ical stimulus Endothelin 1. The additional in vitro studies were per-
formed to examine the molecular mechanisms of SPARC expression at
transcriptional, translational and post-translational levels, withmiRNAs
involvement: they would clarify the in vivo data. The post-translational
mechanism was investigated since SPARC as well as Endothelin 1 are
genes containing 3′-UTR regulatory sequences [21,22], which bind
miR29a and miR98 [23,24]. The miR98 is enhanced by Peroxisome
proliferator activated receptor (PPAR)γ activity [24], which is elevated
in 1833 cells [25]. By binding to the 3′-UTR, miRNAs may control
mRNA degradation or the translational inhibition of cancer associated
protein coding genes [26].
We found that SPARC was highly expressed in bone metastasis and
in the bone-marrow cells, and the blockade of DNA methyltransferases
slowed-down metastasis outgrowth. Notably, dAza reduced not only
SPARC but also Endothelin 1 at the invasive front of bone metastasis
and in supportive cells of the bone marrow. The transcription factor
Twist seemed to be especially involved in the methylation-controlled
signalling pathway for SPARC expression in vivo and in vitro. In 1833
cells exposed to dAza, exogenous miR29a reduced SPARC expression,
and Endothelin 1 transactivation depended on the 3′-UTR. Endothelin
1 protein level was reduced under PPARγ activity, being present
miR98 inmetastatic cells. These features of DNAmethylation pertaining
to SPARC in bone metastasis from breast carcinoma might have func-
tional and therapeutic relevance.
2. Materials and methods
2.1. Materials
dAza was from Cayman Chemical (Ann Arbor, MI, USA). Human
Endothelin 1 Calbiochem® was from Merck Chemicals Ltd.(Nottingham, UK). Anti-SPARC (H-90), anti-Endothelin 1/2/3 (H-38),
anti-Twist 1/2 (H-81) and anti-Akt 1/2/3 (H-136) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphoAkt (pAkt, Ser
473) antibody was from Cell Signaling Technology (Beverly, MA, USA).
Anti-Snail 1/2 antibody (ab53519) was from Abcam (Cambridge, UK).
2.2. Cell lines
The parental breast carcinomaMDA-MB231 cells, the derived 1833-
bone metastatic clone and the 1833 cells, retrovirally transfected with
HSV1-tk/GFP/ﬁreﬂy luciferase (1833/TGL), were kindly given by Dr. J.
Massagué (Memorial Sloan-Kettering Cancer Center, New York). The
comparative study of the transcriptomic proﬁle of the two cell lines
identiﬁes a gene set whose expression pattern is associated with, and
promotes the formation of metastasis to bone [19]. 1833 and MDA-
MB231 cells were authenticated with the method of short-tandem
repeat proﬁling (STR) of nine highly polymorphic STR loci plus
amelogenin on September 2014 (Cell Service from IRCCS-Azienda
Ospedaliera Universitaria San Martino-IST-Istituto Nazionale per la
Ricerca sul Cancro, Genova, Italy). The cells, routinely maintained in
DMEM containing 10% (v/v) FBS, were used after 2 or 3 passages in cul-
ture [27].
2.3. Western blot analysis
We used total extracts (100 μg of protein) from cells exposed to
dAza, Endothelin 1, or troglitazone. dAza (1 μM) was added to the
cells at the time of seeding (1 day) and after 24 h (2 days). For
30 days treatment, dAza (0.1 μM) was added in concomitance with
cell splitting (every 4 days) [28]: for comparison some cells were cul-
tured for 30 days (c30) without treatments. When present, cyclohexi-
mide (100 μg/ml) was added to 1-day or 30-days dAza exposed cells,
and to the respective controls. Then, the protein extracts were prepared
over a 24-h time course. Endothelin 1 (50 ng/ml) was added to starved
cells [2]. Troglitazone was used at the ﬁnal working concentration of
20 μM [25]. Some cells were transfected with 25 nM siRNASnail (ON-
TARGETplus Human SNAI1, SMART pool) or siRNA control (ON-
TARGETplus Non targeting Pool) (Dharmacon, Lafayette, CO, USA)
[29], with 400 ng/ml of the expression vectors for Twist (pCMV-
TWIST) and for Snail, or with 30 nM miR29a-3p mimic or miRcontrol
(Ambion/Life Technologies, Carlsbad, CA, USA) [30]. The antibodies
used for immunoblotting were: anti-SPARC (1:200), anti-Akt (1 μg/
ml), anti-pAkt (1:1000), anti-Endothelin 1/2/3 (1:200), anti-Twist
(1:200) and anti-Snail 1/2 (1:500). SPARC level was also evaluated on
the conditioned medium: 20 x 106 cells were seeded in T75 ﬂasks,
were treated or not for 30 days with dAza, were maintained without
serum for 48 h, and the supernatants from two ﬂasks was pooled [2].
The conditioned medium was harvested, lyophilized and, then,
reconstituted in the loading buffer.
The densitometric analysis of Western blots was performed after
reaction with ECL plus chemiluminescence kit from Thermo Fisher
Scientiﬁc (RockFord, IL, USA).
2.4. Plasmids, siRNA and miRNA transfection, and luciferase activity assay
The cells seeded in 24-multiwell plates, were transfected with
400 ng/ml of the gene reporter for the Endothelin 1 promoter
650(+UTR)Luc (Dr. F. Rodriguez-Pascual, Madrid, Spain), for the
Endothelin 1 promoter 650Luc [31], or for the SPARC promoter
(SPARCLuc, GoClone n° 32001, Active Motif, La Hulpe, Belgium). The
cells transfected with the gene reporters for Endothelin 1, were co-
transfectedwith Renilla luciferase plasmid, and Fireﬂy/Renilla luciferase
activity ratios were calculated by the software. The SPARCLuc activity
was evaluated by following the manufacturer's protocol. Cells
transfected with SPARCLuc in 96 multiwell, were co-transfected with
2 mg/ml of the dominant negative for Runx2 (ΔRunx2), Ets1 (ΔEts1,
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siRNASnail and siRNA control, and were treated or not with dAza for 2
or 30 days, or with Endothelin 1. ΔRunx2, ΔEts1 and ΔTwist were
from Drs. O. Broux (Lille, France), J. Ghysdael (Orsay, France) and E.-
M. Füchtbauer (Aarhus, Denmark), respectively. The transfections of
the gene reporters alone or in the presence of the expression vectors
were performed with a mixture (3:1) of DNA and Fugene 6.
DharmaFECT 4 reagent (Dharmacon) was used for 48 h transfection of
siRNASnail and siRNA control, as well as for 72 h transfection of
miR29a-3p mimic and miRcontrol. Some cells in 96 multiwell were
transfected with 100 ng of the reporter construct containing the 3′-
UTR of SPARC (S810986, LightSwitch, GoClone, Active Motif), using
DharmaFECT Duo (Dharmacon), in the presence of 80 nM miR29a or
miRcontrol. The luminescence was measured with Glomax Discover
System (Promega, Madison, WI, USA).
2.5. Quantitative RT-PCR detection of mRNAs and miR98
For mRNA measurement, total RNA was extracted from 1833 and
MDA-MB231 cells following manufacturer's instructions (TRIzol, Life
Technology, Monza, Italy). Reverse transcription was performed using
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, Monza, Italy).
Gene expression was measured using TaqMan Gene Expression
Assays (Applied Biosystems, Monza, Italy; Endothelin1, Assay ID:
Hs00174961_m1; SPARC/Osteonectin, Assay ID Hs00234160_m1).
GAPDH was used as internal control to normalize the mRNA levels.
For miR98 assay, total RNAwas extracted from 1833 cells using RNeasy
Plus Mini Kit (Qiagen, Valencia, CA, USA) following manufacturer's in-
structions. Reverse transcription and expression were assayed using
mercury LNA™ Universal RT microRNA PCR Starter Kit (Exiqon,
Woburn, MA, USA; hsa-miR-98-5p). SNORD was used as internal
control to normalize the miRNA levels.
2.6. Xenograft model preparation and treatment
The xenograft model was prepared with 1833/TGL cells, injecting
5x105 cells in the left ventricle of 20 nu/nu mice under anaesthesia
[32]. One group of 12 mice underwent concomitant administration of
1833/TGL cells and dAza (5 mg/kg, i.p.), and these mice were subse-
quently treated with dAza once a week until the sacriﬁce [33]; the
other group of 8 mice was administered with the vehicle. The animals
were monitored and sacriﬁced to prevent the suffering, following the
Institutional Guide for Care and Use of Laboratory Animals, and the In-
ternational Laws. Fireﬂy D-luciferine (150 mg/kg) was given intraperi-
toneally under anaesthesia, and metastasis formation was monitored
using Xenogen IVIS 200 System-Perkin Elmer at Istituto San Raffaele,
Milano Italy. Acquisition time for bioluminescence was 5 min at the be-
ginning of the experiment, i.e. 1 h and 24 h after xenografting; for the
following observations, the acquisition timewas reduced to 1min in ac-
cordance with the signal strength, to avoid saturation. Bioluminescence
all over the skeleton (total burden) takes into consideration chosen re-
gions of interest (ROI). The normalization of the data for each animal
was done. For this, the values of ROI at 24 h were evaluated, and used
to normalize the bioluminescence signals detected at each time point
thereafter, a procedure that avoids variations affecting extravasation
and homing due to the treatment.
2.7. Immunohistochemistry
Analyses were performed on ﬁve mice 25 days after 1833 cell injec-
tion, in the presence or the absence of dAza treatment. Femora and
tibiae were ﬁxed and decalciﬁed before preparation of serial sections
[27]. Immunostaining of ﬁve serial sections for each specimen was
performed using anti-SPARC (1:200), anti-Twist (1:200), anti-Snail
(1 μg/ml) and anti-Endothelin 1 (1:50) antibodies. Negative controlswere performed without the speciﬁc antibody. The slides were ex-
amined under Eclipse 80i microscope (Nikon, Milano, Italy).
2.8. Statistical analysis
Densitometric values for protein levels, as well as the values for PCR,
luciferase activities and bioluminescence were analysed by analysis of
variance with P b 0.05 considered signiﬁcant. Differences from controls
were evaluated on original experimental data.
3. Results
3.1. Effect of dAza on SPARC expression in invasive and metastatic breast
carcinoma cells
SPARC protein andmRNA levels and their regulationwere studied in
1833-bone metastatic clone, compared with parental breast carcinoma
MDA-MB231 cells, to clarify whether SPARC expression depended on
the cell phenotype (Fig. 1). In particular, we evaluated the involvement
of the epigenetic mechanisms, considering whether DNA methylation
orchestrated the transcriptional and/or post-translational control of
SPARC expression. This experimental approach was suggested because
the software analysis of SPARC promoter, used in our study, indicated
the presence of numerous putative-methylation sites, beyond binding
sites for the transcription factors Runx2, Ets1, Twist and Snail
(Fig. 1A). For these studies we blocked DNA methyltransferases with
dAza and we assayed the short- and long-term effects. As shown in
Fig. 1B, the 1 or 2 days dAza treatment of both the cell lines increased
SPARC-protein levels, while only in 1833 cells the 30-days culture
(c30) enhanced SPARC-protein level (4-fold), that was almost un-
changed after 30-days dAza. Differently, in c30-MDA-MB231 cells the
SPARC-protein level was very low, i.e. under the control (c) value, in-
creasing after 30-days dAza. Thus, both under basal and dAza conditions
the 1833 cells with bone tropism showed two bands for SPARC of 32–35
and 43 kDa, as reported for the bone [3]; the SPARC basal level was
higher in 1833 than in MDA-MB231 cells.
In the next experiments, we deepened the knowledge of the molec-
ular mechanisms responsible for SPARC expression. First, we evaluated
the SPARCmRNA levels by RT-PCR (Fig. 1C). In 1833 cells SPARCmRNA
level doubled after 2-days dAza in respect to the control; the 30 days
culture induced SPARC mRNA, that was practically unchanged by 30-
days dAza treatment, consistent with the protein levels. In MDA-
MB231 cells, concomitant inductions of SPARC transcript and protein
occurred after short- and long-term dAza treatment.
In MDA-MB231 cells exposed to dAza SPARC regulation seemed to
occur at transcriptional level, while the data suggested a complex regu-
lation of SPARC expression in 1833 cells. To deepen the knowledge in
1833 cells, we performed a second series of experiments in the presence
of cycloheximide (CHX) (Fig. 1D). CHX is an inhibitor of new protein
synthesis, that permits to evaluate the degradation rate of a speciﬁc pro-
tein; a possible stabilizing effect of a chemical substance might be,
therefore, evidenced [34]. CHX treatment under 30-days and 1-day
dAza exposure, increased SPARC-protein levels (3- to 5-fold), in respect
to CHX added alone to the respective controls: these ﬁndings suggested
that dAza enhanced SPARC half-life leading to the stabilization (Fig. 1D
graphic). The data suggested that in dAza-treated 1833 cells different
mechanisms might underlie the increases in SPARC protein at 1 and
2 days, thatwere due to protein stabilization (at 1 day) and to enhanced
transcription (at 2-days).
Notwithstanding the increase of SPARC protein half-life after
30-days dAza (Fig. 1D), the steady-state protein level of SPARC did not
augment (Fig.1B), compared with c30. This was explained because of
SPARC release from 30-days dAza-treated 1833 cells, as demonstrated
by SPARC accumulation in the conditioned medium (Supplementary
Fig. S1A).
Fig. 1. Effect of dAza treatment on SPARC expression in 1833 and MDA-MB231 cells. (A) transcription-factor binding sites and methylation islands in SPARC promoter are shown. DNA
methylation is characterized by an enzymatic addition of a methyl group at the carbon 5 position of cytosine in the context of the sequence 5′ cytosine-guanosine (CpG) through DNA
methyltransferase activity. CpG dinucleotides are clustered in regions, named CpG islands. (B) representative images of Western blots repeated three times are shown; vinculin was
used for normalization. The numbers at the bottom indicate the fold variations versus control (c) value of 1833 cells, considered as 1. (C) RT-PCR of total RNA was normalized for
GAPDH values. The data are themeans ± S.E. of three independent experiments performed in triplicate. *P b 0.05, **P b 0.005, versus the control value for each cell line; ○P b 0.05, versus
c30. (D) representative images ofWestern blots performedwith proteins from cells treated or notwith cycloheximide (CHX), in the presence or the absence of dAza. Vinculinwas used for
normalization. The data shown in the graphic are themeans± S.E. of three independent experiments. §P b 0.05, §§P b 0.005 versus the value at the same time of c+ CHX or of c30+ CHX;
*P b 0.05, **P b 0.005 versus the respective control values at time 0. (E) the histogram indicates the absolute values of SPARCLuc, in respect to Cypridina-luciferase internal control, under
various experimental conditions. The data are the means ± S.E. of three independent experiments performed in triplicate. *P b 0.05, versus basal SPARCLuc activity value (ﬁrst white
column); ΔP b 0.05, versus SPARCLuc value under 2-days dAza; •P b 0.05, versus SPARCLuc value under 30-days dAza.
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exposed or not to dAza, we studied SPARC transactivation and the
transcription factors involved. To this purpose, we used the dominant
negatives for the transcription factors, with consensus sequences in
the promoter [35–37], and siRNASnail [29] (Fig. 1E). The dominant neg-
atives forms of the transcription factors, are partially deleted proteins
maintaining only the DNA-binding domain, and they have beenpreviously used in our papers to evaluate the involvement of Twist,
Runx2 and Ets1 in gene transactivation [2,5,38]. Because of the high af-
ﬁnity of the dominant negatives for the speciﬁc consensus sites, without
showing transactivating activity, they inhibit the promoter activity
depending on their functional involvement. For Snail, the dominant
negative does not exist and, therefore, we used a speciﬁc siRNA to re-
duce the protein level of Snail in 1833 cells (Supplementary Fig. S1B).
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terfere with the translation of proteins by binding to and promoting the
degradation of the speciﬁc mRNAs [29].
SPARCLuc was activated in the cells maintained in culture for
30 days (c30) or under 2-days dAza, in respect to SPARCLuc basal
value (ﬁrst white column); these data were consistent with the mRNA
levels. ΔTwist reduced basal SPARCLuc activity, indicating a role of this
transcription factor in SPARC transactivation. Runx2, Ets1 and Twist
were involved in the transactivation of SPARC under 30-days dAza.
siRNASnail was ineffective on SPARCLuc activity, even if it reduced the
Snail protein level in 1833 cells (Supplementary Fig. S1B). The effective-
ness of dAza in 1833 cells was evaluated by studying the Akt-signalling
pathway, that is downstream of phosphatase and tensin homolog
(PTEN): the latter is a target gene of methyltransferases and is activated
by dAza [33] (Supplementary Fig. S1C).
3.2. Effect of dAza on bone metastasis outgrowth and SPARC expression in
the xenograft model
To give new insight into the effect of DNA-methylation status on
survival of mice bearing bone-metastasis, related to the molecularFig. 2. dAza affected bone-metastasis outgrowth. (A) representative bioluminescence images
changes in total burden is shown for ME mice, until their death at 26 days, and for ME + dAza
those at 4 days, and the percentages of inhibition. The data are the means ± S.E. of the value
value at the corresponding time.characteristics, we treated the 1833-xenograft mice with dAza. To this
purpose, we studied the cooperativity of SPARCwith themolecular net-
work important for epithelial–mesenchymal transition, that includes
Twist and Snail transcription factors and the other biological stimulus
Endothelin 1 [2,5].
As shown in Fig. 2A, we monitored the metastatic development in
real-time, exploiting the time-course of bioluminescence of mice bear-
ing bone metastasis (ME), compared with ME treated with dAza. All
thedatawere normalized versus bioluminescence at 24h, and the injec-
tion efﬁciencywas controlled bymonitoring the bioluminescence signal
1 h after xenografting (Supplementary Fig. S2A).
As shown in Fig. 2B, dAza treatment reduced the total burden
starting from 9 days reaching the highest inhibitory effect at 22 days,
when the percent of inhibition was 74% (see Table). ME mice died at
26 days on average [32], and dAza treatment positively inﬂuenced
mice survival, so that ME + dAza mice were sacriﬁced between 31
and 38 days.
Fig. 3 shows the immunohistochemical analyses of SPARC in control
bone, and in the bone ofME andME+dAza. In control bone, SPARC ex-
pression was found in chondrocytes of calciﬁed cartilage (c) and in os-
teoblasts (o), according to the literature [3]. In osteoblasts, the signalof three xenograft mice for each experimental group (n = 5). (B) The time-course of the
mice until 33 days from xenografting. The Table reports the total burden data, including
s for ﬁve mice. §§§P b 0.001, versus ME value at 4 days; *P b 0.05, ***P b 0.001, versus ME
Fig. 3. SPARC signal in the bonemetastasis of the xenograft model, and effect of dAza treatment.We show representative images of control bone, and of bone-metastasis tissue frommice
treated or not with dAza. Five serial sections were examined for each specimen from ﬁve mice, obtaining similar results, and the original magniﬁcation is shown. c, chondrocytes; o,
osteoblasts; ot, osteoid tissue; gp, growth plate; bm, bone marrow; bo, bone; mk, megakaryocytes; me, metastasis. Scale bar = 120 μm (reported in exempliﬁcative Panels 20×, 40×
and 60×).
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marrow was observed in the megakaryocytes (mk) and in the
mesenchymal-stromal cells. In ME mice, SPARC signal was highly
expressed in metastatic cells, both in the cytosol and the nuclei, but
showing different intensity throughout the bone metastasis. In nuclei,
SPARC may inﬂuence the cell cycle [39]. In the bone marrow of ME
mice, the SPARC signals of megakaryocytes and the other supportive
cells were higher than those found in control bone. After dAza treat-
ment, the metastatic SPARC signal remained elevated in the metastasis
bulk, but disappeared from the front lining the bone and from the bone
marrow. Negative controls did not show speciﬁc signal. All the animalsshowed similar responsiveness to dAza treatment as regards SPARC
signal (data not shown), consistent with the ﬁndings reported for
mice dAza5.
Next, we performed experiments to identify molecular events re-
sponsible for the down-regulation of SPARC under dAza. Notably,
dAza induces miR29a [30], that targets the 3′-UTR of SPARC [23]. Since
miR29a in 1833-parental cells is very low [40],we transfected a synthet-
ic miRNA mimic to overexpress the mature form of miR29a in 1833
cells. This experiment permitted to evaluate the biological function of
miR29a. As shown in Fig. 4, the transfection of the speciﬁc miR29a
mimic strongly reduced SPARC protein levels in controls (c and c30)
Fig. 4. Effect of miR29a on SPARC protein levels, and on the 3′-UTR luciferase activity.
(A) miR29a mimic was transfected into 1833 cells, untreated or treated with 1 μM dAza
for 2 days, or exposed to 0.1 μM dAza for 30 days. Representative images of Western
blots repeated three times are shown; vinculin was used for normalization. The numbers
at the bottom indicate the fold variations versus control (c) value of miRcontrol
transfected cells, considered as 1. (B) the SPARC-3′-UTRLuc was transfected together
with miRcontrol or miR29a for 24 h. The data are the means ± S.E. of three independent
experiments performed in triplicate. *P b 0.05, versus the value of SPARCLuc in the pres-
ence of miRcontrol.
Fig. 5. Effects of dAza on Twist and Snail protein levels, and inﬂuence of their overexpres-
sion on SPARC and Endothelin protein levels. The cells were (A) treated with dAza or
(B) transfected with Twist and Snail expression vectors (e.v.). Representative images of
Western blots repeated three times are shown; vinculin was used for normalization. The
numbers at the bottom indicate the fold variations versus the ﬁrst lane, considered as 1.
Whenmultiple bands for a speciﬁc proteinwere present, theywere considered altogether
in the densitometric evaluation, used to calculate the fold-variations.
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sponding miRcontrol transfected cells (Fig. 4A). The speciﬁcity of
miR29a for the regulatory sequence of SPARC promoter was demon-
strated by measuring the SPARC-3′-UTR activity. The luciferase activity
of SPARC-3′-UTR decreased (−60%) in 1833 cells transfected with
miR29a, in agreement with the diminutions of SPARC protein level.
miRcontrol was ineffective on SPARC-3′-UTR activity (Fig. 4B).
3.3. Effect of dAza on the expression of Twist and Snail in vitro and in bone
metastasis of the xenograft model
In further experiments we evaluated whether Twist and Snail were
implicated in SPARC expression depending on the methylation status.
These transcription factors, showing consensus sequences in SPARC
promoter, are regulated by DNA methyltransferases in breast cancer
[41,42].
Fig. 5A shows that in 1833 cells, short-term exposure to dAza
enhanced only Twist protein level. Importantly, the 30-days culture
per se caused the accumulation of Twist and Snail proteins, that de-
creased of about 45% at 30 days of dAza exposure, a treatment similar
to that performed in vivo. Thus, it seemed interesting to evaluate the
effects of Twist and Snail overexpression on the biological stimuli exam-
ined in the present paper (Fig. 5B), and experiments were performed
with the expression vectors for Twist and Snail. Under the forced ex-
pression of Twist and Snail, SPARC steady-state protein level doubled;
only Snail expression vector strongly enhanced the three forms of
Endothelin.
Altogether, the in vitro studies suggested to examine Twist and Snail
signals in the xenograftmodel under dAza. As shown in Fig. 6, Twist andSnail appeared remarkably expressed in bone metastasis, in all the
compartments of the metastatic cells, and in the bone marrow cells.
The effect of dAza treatment is shown for the mice 1 and 5. In both
these ME+ dAza mice, Twist signal was impaired in the metastatic tis-
sue, including the bone marrow. The Snail signal decreased more in the
bone metastasis of dAza5 than of dAza1, the latter mouse showing
major metastasis outgrowth. For both the dAza mice, Snail signal
seemed more persistent in the bulk of metastasis than in the front,
and diminished in the bone marrow. Negative controls did not show
speciﬁc signal. To support these results, in Supplementary Fig. S3 we re-
port Twist and Snail immunohistochemical assays for the bonemetasta-
ses of the other animals examined. Also for the mice dAza 3, 6 and 8 we
showed down-regulation of Twist and Snail signals in metastasis and
bone marrow, compared to ME mice.
The in vivo data of Fig. 6 and Supplementary Fig. S3 indicated that in
bone metastasis Twist expression was mainly affected by methylation
status, being largely reduced by DNA methyltransferase blockade
in vivo, consistent with the in vitro data (Fig. 5).
3.4. Involvement of Endothelin 1 in the regulation of SPARC expression, and
response of Endothelin 1 to DNA methyltransferase blockade
To evaluatewhether the cellular expression of SPARCwas coordinat-
ed with that of Endothelin 1, another biological stimulus important for
the osteomimetic phenotype and for tumour-stroma cross-talk [2,43],
we studied SPARCLuc activity and the steady-state protein levels of
Fig. 6. Twist and Snail signals in the bone metastasis of the xenograft model, and effect of dAza treatment. Representative images of bone-metastasis tissue frommice treated or not with
dAza are shown. Five serial sections were examined for each specimen from ﬁvemice, obtaining similar results, and the original magniﬁcation is shown. gp, growth plate; bm, bonemar-
row; bo, bone; me, metastasis. Scale bar = 120 μm (reported in exempliﬁcative Panels 20×, 40× and 60×).
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hanced SPARCLuc activity in 1833 but not in MDA-MB231 cells, and
ΔRunx2 as well as ΔTwist prevented the luciferase activation. siRNA
Snail and siRNA control did not affect Endothelin 1-stimulated SPARCLuc
activity. siRNA control was ineffective also on basal SPARCLuc activity
(data not shown). In 1833 cells, Endothelin 1 increased SPARC-protein
level between 6 and 16 h, diminishing thereafter towards the control
level, while SPARC protein level was unaffected by Endothelin 1 in
MDA-MB231 cells. Twist and Snail oppositely responded to Endothelin
1. In 1833 cells, Endothelin 1 increased Twist at 24 h while reducing
Snail; opposite patterns were observed in MDA-MB231 cells (Fig. 7B).From the analysis of Endothelin 1 promoter, wide CpG islands with
49 putative methylation sites, and 2 Snail without Twist consensus se-
quences were found (Fig. 8A), leading to suppose a possible implication
of DNA methyltransferases in the expression of Endothelin 1, shown to
be important for SPARC induction. Fig. 8B shows the effect of dAza on
the steady-state protein levels of the members of Endothelin family:
the relative fold-variations, calculated using the densitometric values,
are reported in the histograms. The Endothelin family consists in three
isoforms [43]. While 30-days culture enhanced especially Endothelin 3
protein level in 1833 andMDA-MB231 cells, 30-days dAza strongly aug-
mented Endothelins 1 and 2 only in 1833 cells.
Fig. 7. Effects of exogenous Endothelin 1 on SPARC transactivation as well as on SPARC,
Twist and Snail expression. (A) the histograms indicate the absolute values of SPARCLuc,
in respect to Cypridina-luciferase internal control, under various experimental conditions.
The data are the means ± S.E. of three independent experiments performed in triplicate.
*P b 0.05, versus basal SPARCLuc value; ΔP b 0.05, versus the luciferase value under
Endothelin 1 treatment. (B) representative images of Western blots repeated three
times are shown; vinculinwas used for normalization. The numbers at the bottom indicate
the fold variations versus 1833-starvation value, considered as 1.
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molecular basis to devise the following in vivo experiments. First, the
messenger level of Endothelin 1 almost tripled under 30-days dAza
(Fig. 8C), indicating that the enhancement of the protein level depended
on transcription. These data on the enhancement of endogenous
Endothelin 1 under blockade of DNA methyltransferases, supported an
effective mimicking function of exogenous Endothelin 1 on SPARC
expression.
Second, due to the presence of a 3′-UTR sequence, ﬂanking
Endothelin 1-promoter (see Fig. 8D, Scheme) [22], we examined
whether a post-transcriptional control might occur under our experi-
mental conditions; this regulatory sequence is important for mRNA
degradation or inhibition of translation [26].Weused the gene reporters
containing the Endothelin 1 promoter, with or without the 3′-UTR. As
shown in Fig. 8D (histogram), while the activity of Endothelin 1 lucifer-
ase construct containing the 3′-UTR decreased under 30-days dAza, in
the absence of the 3′-UTR the same dAza treatment gave a stimulation.
The latter ﬁnding, which was in agreement with the Endothelin 1 pro-
tein induction, also indicated that the 3′-UTR was offside in 1833 cells
exposed to 30-days dAza. Of note, the removal of 3′-UTR in the con-
struct decreased c30 luciferase activity.
To obtain more data on this post-transciptional regulation, depen-
dent on the 3′-UTR activity, we evaluated Endothelin expression and
miR98 level under troglitazone, an activator of PPARγ [25]. In fact,miR98 is known to be enhanced by PPARγ activity, and to bind directly
to the 3′-UTR of Endothelin 1 [24]; PPARγ is functional in 1833 cells
[25]. Fig. 8E shows that in 1833 cells treated with troglitazone for 24
and 48 h, Endothelin 1 protein level decreased of 60 and 80% at the
two times, while the isoforms 2 and 3 diminished of 70 and 40% only
at 48 h. Under the same experimental condition in the presence of
troglitazone, miR98 relative value was 6.39, in respect to the expression
of the internal control SNORD.3.5. Expression of Endothelin 1 in bone metastasis and effect of dAza
To examine the interaction of Endothelin 1 and SPARC in vivo, and
the role of methylation status, we studied the effect of dAza treatment
of the xenograft mice on Endothelin 1. In control bone, Endothelin 1 sig-
nal was found in mesenchymal-stromal cells of the bone marrow
(Fig. 9A). InMEmice, themetastatic cells strongly expressed Endothelin
1, and the bone marrow signal was similar to that observed in control
bone. After dAza treatment, Endothelin 1 signal disappeared frommet-
astatic cells lining the bone, but not from the bulk of metastasis, as ob-
served for SPARC pattern in the same samples. Endothelin 1 signal
disappeared under dAza treatment also in the bone marrow. Negative
controls did not show speciﬁc signal. All the animals showed similar re-
sponsiveness to dAza treatment as regards Endothelin 1 signal (data not
shown), consistent with the ﬁndings reported for mice dAza5.
In conclusion, the key roles of 3′-UTR function as well as of the ex-
pression of mi98 might explain why in vivo Endothelin 1 decreased
while it augmented in 1833 cells: even if the schedule of ﬁve adminis-
trations of dAza in vitro was similar to that performed in vivo the net-
work of signalling is different.4. Discussion
The present paper deals for the ﬁrst time with the expression and
regulation at epigenetic level of endogenous SPARC, and with its role
in the establishment of bonemetastasis from breast carcinoma. The ap-
proach to use dAza to block DNA methyltransferases in vivo, was a tool
to clarify the biological function of SPARC regulated by methylation in
the pathogenesis of bone metastasis. These ﬁndings with 1833-
xenograft model were corroborated by in vitro experiments. In fact,
we clariﬁed molecular mechanisms underlying aberrant SPARC expres-
sion depending on bone metastatic versus invasive phenotype, the
surrounding-environmental signals such as Endothelin 1, and the
DNA-methyltransferase activity. Notably, the microenvironment may
inﬂuence the methylation status of tumour cell DNA [44].
The 1833-bone metastatic cells constitutively expressed twomolec-
ular weight forms of SPARC as the bone, possibly due to glycosylation
[45], that might confer osteomimetic properties and permit the interac-
tionwith platelets, at a differencewithMDA-MB231 cells [11]. Since the
timing of SPARC expression is important for metastatization, these mo-
lecular characteristics of 1833 cells might favour bone-metastasis out-
growth, in contrast to MDA-MB231 cells with low level of endogenous
SPARC protein. MDA-MB231 cells are mesenchymal and invasive, with
scarce metastatic power and tropism for different organs [11], giving
metastasis to bone less efﬁciently and more slowly than 1833 cells
with epithelial phenotype [5,19,27].
It is worth noting that in the 1833-xenograft model, SPARC expres-
sionwas elevated both in bonemetastasis and in the bone-marrow sup-
portive cells. These data led to suppose that SPARC might play a critical
role in the cross-talk between metastatic and microenvironmental cells
likely by triggering signals for outgrowth and bone-matrix remodelling
[21]. This hypothesis is under investigation, since the host stroma has
crucial roles in each step of the metastatic process, and the bone
marrow cells are important in the establishment of overt, immune-
suppressed metastatic lesions [1].
Fig. 8. Transcriptional and post-transcriptional control of Endothelin 1 expression by dAza. (A) Snail binding sites andmethylation islands in the entire Endothelin 1 promoter are shown.
(B) representative images of Western blots repeated three times are shown; vinculin was used for normalization. The data reported in the histograms were calculated by using the den-
sitometric values, and were themeans± S.E. of three independent experiments. ΔP b 0.05, versus control (c) value; **P b 0.005, versus c30 value. (C) RT-PCR of total RNAwas normalized
for GAPDH values. The data are the means ± S.E. of three independent experiments performed in triplicate. **P b 0.005, versus control (c) value. (D) scheme of Endothelin 1 promoter
constructs of 650 bp with or without the 3′-UTR. The histogram shows the absolute values of luciferase activity for the two constructs transfected in c30 cells or in the cells exposed to
dAza for 30 days. The data are the means ± S.E. of three independent experiments performed in triplicate. *P b 0.05, versus the value of Endothelin 650(+UTR)Luc in c30 cells;
OP b 0.05, versus the value of Endothelin 650Luc in c30 cells. (E) samples of proteins (100 μg) from 1833-c30 cells, exposed or not to troglitazone, were used for Western blot assay.
The experiment was repeated three times, and a representative image is shown; vinculin was used for normalization. The numbers at the bottom indicate the fold variations for each
Endothelin form versus the ﬁrst lane, considered as 1.
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sor”, is highly expressed in human bone metastasis and is regulated by
methylation [25,46]. SPARC in tumours inﬂuences metalloproteinase
production and focal adhesion regulation [6]: these functions of SPARC
might be important for metastasis engraftment by forcing the endothe-
lial junctions at secondary bone site, and for an intermediate state of
adhesion. Moreover, SPARC enhances VEGF expression [47] and
Wwox regulates the activity of HIF-1, the transcription factor that
transactivates VEGF [48].Explanations atmolecular level for SPARC expression in bonemetas-
tasiswould be given byDNAmethylation (hyper- or hypo-methylation),
that leads to aberrant gene transcription, consistent with the control of
suppressor-genes promoters by methyltransferases and indicating an
interactive link between aberrant-promoter methylation and cancer
metastasis [16,49]. Even if the role of DNA methylation in bone metas-
tasis from breast cancer has been scarcely investigated [41], we were
encouraged to undertake the present study because DNA methyltrans-
ferase blockade with dAza affects miRNA activity [30], and miRNAs are
Fig. 9. Endothelin 1 signal in the bonemetastasis of the xenograft model, and effect of dAza treatment. (A) we show representative images of control bone, and of bone-metastasis tissue
from mice treated or not with dAza. Five serial sections were examined for each specimen from ﬁve mice obtaining similar results, and the original magniﬁcation is shown. gp, growth
plate; bm, bone marrow; bo, bone; me, metastasis. Scale bar =120 μm (reported in exempliﬁcative Panels 20× and 40×). (B) schematic representation of SPARC regulation in bone
metastasis.
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[50].
We observed that dAza exposure slowed-down metastasis out-
growth starting from 9 days of xenografting until the end of the obser-
vation period, with the prolongation of mice survival until 38 days in
respect to 26 days of metastasis-bearingmice. The complete prevention
of SPARC expression in the bone marrow supporting the metastatictissue, would contribute to the favourable outcomeunder dAza. Increas-
ing evidence accumulates on the contribution of the host-bone micro-
environment to metastatic progression [1]. The present results with
dAza given to the xenograft mice represent an advancement in respect
to 5′-Azacytidine treatment of the 1833 cells in vitro, that changes 1833-
bone tropism towards lung after xenografting [25] and that is converted
to dAza for incorporation into DNA [20].
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microenvironment are complex, but fall into two main categories:
contact-dependent mechanisms that involve cell-cell and cell-ECM ad-
hesion molecules [51], and contact-independent mechanisms carried
out by soluble molecules such as growth factors, chemokines and cyto-
kines, and soluble cellular organelles including microvesicles and
exosomes [17]. In our conditions, microenvironmental stimuli like
Endothelin 1 might ensure SPARC up-regulation in bone osteogenic
niches with successful metastasis formation. Consistently, exogenous
Endothelin 1 induced SPARC through Runx2, conferring osteomimicry
to bone-metastatic cells.
Altogether, endogenous Endothelin 1 as SPARC disappeared from
the front of bone metastasis and in the bone marrow of the xenograft
mice under dAza, supporting their coordinate function. The partial resis-
tance of Snail to DNA-methylation blockade might explain the
Endothelin 1-SPARC interaction in the bulk of metastasis, in agreement
with the role of Snail in orchestrating the supportive pathways from the
microenvironment, but in an opposite way to Twist [5].
In bone metastatic cells, Snail is a target gene of TGF-β1 while HGF
triggers a Twist program [5], and also TGF-β1 up-regulates and HGF
down-regulates Endothelin 1 expression and release [2]. Thus, metasta-
tic SPARC is in a wider context of biological stimuli of bone-metastasis
microenvironment including Endothelin 1, and is responsive tomethyl-
transferases, through a network of transcription factors including Twist,
Snail and Runx2, as shown in Fig. 9B. Endothelin 1 activates not only
Runx2 [2] but also Twist, as reported in the present paper.
Extensive studies were performed to clarify the patterns of
Endothelin 1 in vivo and in vitro under long-term dAza exposure. In
particular, we evaluated the function of the 3′-UTR of the gene and
the regulation by miR98, since a post-transcriptional control might be
explanatory. miR98 interacts with Endothelin 1-3′-UTR [24]. We
showed that the regulatory function of the 3′-UTR was fundamental
for the transactivating activity of Endothelin 1, and the induction of
Endothelin 1 occurred when the 3′-UTRwas offside, while the presence
ofmiR98 expressionwas consistentwith Endothelin 1 down-regulation
in the xenograft model. Also, SPARC down-regulation under dAza ad-
ministration seemed to involve a post-transcriptional control, based
on in vitro experiments using miRNA 29a mimic for a functional
analysis.
In conclusion, transcriptional, post-transcriptional and post-
translational (stabilization, glycosylation) mechanisms were responsi-
ble for SPARC expression in bone metastasis. The acquisition of stromal
traits by bonemetastasis is a negative predictive factor, but may also be
a potential therapeutic target [46,52]. Our ﬁndings suggest that
targeting SPARC expression by DNA methyltransferases blockade, and
the combined treatment with miRNAs is a promising strategy to affect
the invasive front of bone metastasis. Methylation of gene promoters
is, in fact, reversible inﬂuencing gene expression,metastasis phenotype,
and the outgrowth of bone metastasis.
Supplementary data to this article can be found online at http://dx.
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